<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nadofaragene firadenovec: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nadofaragene firadenovec: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nadofaragene firadenovec: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="140406" href="/d/html/140406.html" rel="external">see "Nadofaragene firadenovec: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58508360"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Adstiladrin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F57863775"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Biological Response Modifier;</li>
<li>
                        Gene Therapy, Adenovirus;</li>
<li>
                        Interferon</li></ul></div>
<div class="block doa drugH1Div" id="F57863798"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae98d710-7e67-4afb-b0db-3319919e0a5c">Bladder cancer, high-risk, BCG-unresponsive non–muscle invasive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bladder cancer, high-risk, BCG-unresponsive non–muscle invasive: Note: </b>Premedication with an anticholinergic is recommended prior to each nadofaragene firadenovec instillation to minimize irritative voiding symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33253641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33253641'])">Ref</a></span>). Individuals who are immunosuppressed or immune-deficient should not prepare, administer, or come into contact with nadofaragene firadenovec.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intravesicular: </b>75 mL (at a concentration of 3 × 10<sup>11</sup> viral particles [vp]/mL) instilled once every 3 months into the bladder via a urinary catheter for up to 12 months (total of 4 doses) or until disease progression or unacceptable toxicity; may continue beyond 12 months in patients without evidence of high-grade recurrence. If patient does not have a complete response to treatment after 3 months or if carcinoma in situ recurs, consider cystectomy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33253641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33253641'])">Ref</a></span>). Refer to protocol for further information.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F57863800"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F57863801"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F57863799"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F57607473"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum phosphate (16%), increased serum glucose (38%), increased serum triglycerides (30%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Bladder spasm (20%), dysuria (16%), hematuria (17%), urinary urgency (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin (16%; grades 3/4: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site discharge (33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (16%), fatigue (24%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute coronary syndrome (1%), atrial fibrillation (1%), coronary artery disease (1%), syncope (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (1%), hypoglycemia (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart failure, pericarditis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Choledocholithiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Brain edema</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Genitourinary: Bladder neoplasm (benign)</p></div>
<div class="block coi drugH1Div" id="F57599831"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Prior hypersensitivity reactions to interferon alfa or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F57863787"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Risk of muscle-invasive or metastatic bladder cancer: Delaying cystectomy in patients with BCG-unresponsive carcinoma in situ (CIS) may lead to the development of muscle-invasive or metastatic bladder cancer. The risk of developing more advanced or metastatic disease increases the longer cystectomy is delayed (in the presence of persisting CIS). Of the patients with CIS who received nadofaragene firadenovec and later underwent subsequent radical cystectomy, 14% had muscle-invasive (T2 or greater) disease at cystectomy. The median time from persistence or recurrence of CIS to cystectomy was 235 days (range: 38 to 582 days). Consider cystectomy if complete response to nadofaragene firadenovec does not occur after 3 months or if CIS recurs</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Risk of disseminated adenovirus infection: Low levels of replication-competent adenovirus may be present in nadofaragene firadenovec. Immunocompromised patients (including those receiving immunosuppressive therapy) may be at risk for disseminated adenovirus infection.</p></div>
<div class="block foc drugH1Div" id="F58508361"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Intravesical [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adstiladrin: Nadofaragene Firadenov-vncg 300 billion vp/mL (1 ea) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F58508359"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block adm drugH1Div" id="F57863802"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intravesicular:</b> Nadofaragene firadenovec is for intravesicular (bladder instillation) administration only; do not administer IV, orally, or topically. Individuals who are immunosuppressed or immune-deficient should not prepare, administer, or come into contact with nadofaragene firadenovec. Bring to room temperature prior to administration. Premedication with an anticholinergic is recommended prior to each instillation to minimize irritative voiding symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33253641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33253641'])">Ref</a></span>). Refer to manufacturer's labeling for further information.</p>
<p style="text-indent:-2em;margin-left:4em;">Insert a straight, or intermittent, urinary catheter with a proximal funnel opening that will accommodate the Luer lock adapter; use catheters made of vinyl/PVC (uncoated or coated with hydrogel), red rubber latex, or silicone only to instill nadofaragene firadenovec. Do not use catheters coated or embedded with silver or antibiotics. Use the catheter to completely empty the patient's bladder. Do not remove the catheter.</p>
<p style="text-indent:-2em;margin-left:4em;">Attach the Luer lock end of the same catheter adaptor to the syringe containing nadofaragene firadenovec and insert the tapered end of the catheter adaptor into the funnel opening of the catheter. Slowly instill 75 mL of nadofaragene firadenovec into the bladder through the catheter; ensure that the complete volume is instilled.</p>
<p style="text-indent:-2em;margin-left:4em;">Retain nadofaragene firadenovec in the bladder for 1 hour. Patient should reposition approximately every 15 minutes from left to right, back, and abdomen to maximize bladder surface exposure. If the patient experiences bladder cramping or premature voiding during the dwell time, repositioning may be adjusted or discontinued.</p>
<p style="text-indent:-2em;margin-left:4em;">Evacuate nadofaragene from the bladder as part of routine bladder emptying, or the patient may void and completely empty the bladder after 1 hour has elapsed. For 2 days following administration, disinfect voided urine for 15 minutes with an equal volume of virucidal agent before flushing the toilet.</p></div>
<div class="block use drugH1Div" id="F57599830"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Bladder cancer, high-risk, BCG-unresponsive non–muscle invasive:</b> Treatment of high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non–muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors in adults.</p></div>
<div class="block mst drugH1Div" id="F57863772"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Nadofaragene firadenovec may be confused with etranacogene dezaparvovec, onasemnogene abeparvovec, voretigene neparvovec.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F57635172"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F57635169"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased.<i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F57863784"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to treatment initiation in patients who could become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who could become pregnant should use effective contraception during therapy and for 6 months after the last dose of nadofaragene firadenovec. Patients with partners who could become pregnant should also use effective contraception during therapy and for 3 months after the last nadofaragene firadenovec dose.</p></div>
<div class="block pri drugH1Div" id="F57863785"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted with nadofaragene firadenovec.</p></div>
<div class="block brc drugH1Div" id="F57863786"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if nadofaragene firadenovec is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F57863804"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Verify pregnancy status prior to therapy initiation (in patients who could become pregnant). Monitor for development of muscle-invasive or metastatic bladder cancer. Monitor for disseminated adenovirus infection.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F57863791"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Nadofaragene firadenovec is a nonreplicating adenoviral vector-based gene therapy. It consists of rAd-IFNα, a nonreplicating recombinant adenovirus (serotype 5) vector-based gene therapy that transports a copy of interferon alfa-2b gene to urothelial cells, and Syn3, a polyamide surfactant that augments the viral transduction of the urothelium (Boorjian 2021). Intravesicular administration produces cell transduction and transient local expression of the IFNα2b protein, which is believed to have antitumor effects.</p></div>
<div class="block phk drugH1Div" id="F57863792"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: In a phase 2 study, all patients had quantifiable concentrations of IFNα2b protein in the urine at day 2 after nadofaragene firadenovec administration; measurable concentration of urine IFNα2b protein was detected up to day 12 post dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: In clinical studies where nadofaragene firadenovec 3 × 10<sup>11</sup> viral particles [vp]/mL was administered, 1 patient had detectable levels of vector DNA at day 14 (phase 1 study) and most patients had detectable levels of vector DNA at day 12 (phase 2 study).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Ferring.1">
<a name="Ferring.1"></a>Adstiladrin (nadofaragene firadenovec) [prescribing information]. Kuopio, Finland: Ferring Pharmaceuticals; September 2023.</div>
</li>
<li>
<div class="reference">
                  Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33253641">
<a name="33253641"></a>Boorjian SA, Alemozaffar M, Konety BR, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. <i>Lancet Oncol.</i> 2021;22(1):107-117. doi:10.1016/S1470-2045(20)30540-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadofaragene-firadenovec-drug-information/abstract-text/33253641/pubmed" id="33253641" target="_blank">33253641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadofaragene-firadenovec-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadofaragene-firadenovec-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):313. doi:10.1034/j.1600-0536.2002.4705104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadofaragene-firadenovec-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadofaragene-firadenovec-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313. doi:10.1016/s0140-6736(95)90963-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nadofaragene-firadenovec-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 140383 Version 18.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
